HB 3717: Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.

Plain-language summary

HB 3717 is a bill introduced in the Texas House on March 4, 2025. According to its official title, it concerns: Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy. Primary sponsor: Cody Harris (Republican), Jeff Leach (Republican), Dade Phelan (Republican), Angelia Orr (Republican), VanDeaver. It lists 29 additional sponsors. Most recent recorded action (May 12, 2025): Laid on the table subject to call.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written